Abstract
What’s known on this subject One published U.S. study with 31 breastfeeding women who were vaccinated with either of the two available mRNA COVID-19 vaccines found that 67% experienced any side effects after dose one and 61% after dose two of the vaccine.
What this study adds More than 85% of 180 breastfeeding women who received an mRNA COVID-19 vaccine reported local or systemic symptoms, with higher frequency following the second dose. Few symptoms were reported in their breastfed children. No serious adverse events were noted.
Contributors’ Statement Page Dr. Chambers and Ms. Bertrand designed the study and supervised the collection of data used in the study. Mr. Honerkamp-Smith performed the statistical analysis. All authors were involved in preparing the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Competing Interest Statement
Dr. Chambers receives research funding from the following industry sponsors and a foundation: Amgen Inc.; AstraZeneca; Celgene; GlaxoSmithKline; Janssen Pharmaceuticals; Pfizer, Inc.; Regeneron; Hoffman La-Roche-Genentech; Genzyme Sanofi-Aventis; Takeda Pharmaceutical Company Limited; Sanofi; UCB Pharma, USA; Sun Pharma Global FZE; Gilead; and the Gerber Foundation.
Funding Statement
Funding for this study was in part provided by a supplement to NIH-NICHD R21 Grant Number 1R21HD104412-01 to Christina Chambers
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the University of California San Diego institutional review board and all participating women provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosures Dr. Chambers receives research funding from the following industry sponsors and a foundation: Amgen Inc.; AstraZeneca; Celgene; GlaxoSmithKline; Janssen Pharmaceuticals; Pfizer, Inc.; Regeneron; Hoffman La-Roche-Genentech; Genzyme Sanofi-Aventis; Takeda Pharmaceutical Company Limited; Sanofi; UCB Pharma, USA; Sun Pharma Global FZE; Gilead; and the Gerber Foundation.
Funding/Support Funding for this study was in part provided by a supplement to NIH-NICHD R21 Grant Number 1R21HD104412-01 to Christina Chambers
Data Availability
Data access may be provided, with appropriate ethics approval, by contacting the authors
